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Abstract 
Elective total knee arthroplasty (TKA) is the most frequently performed inpatient surgical 
procedure in the United States (Kurtz, Ong, Lau, Mowat, & Halpern 2007). Complications of this 
procedure include deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively 
referred to as venous thromboembolism (VTE). Various pharmacological agents exist for VTE 
prophylaxis. Warfarin and low-molecular-weight heparin (LMWH) were commonly used for VTE 
prophylaxis in the past, but with the emergence of novel anticoagulants including factor Xa 
inhibitors and direct thrombin inhibitors (DTIs), warfarin is used far less frequently. Aspirin is 
also approved for VTE prophylaxis. The purpose of this study was to determine if a superior drug 
or combination of drugs exist for VTE prophylaxis based on patient outcomes, cost effectiveness, 
and risk profile. This review of literature analyzed studies from the past 10 years that compared 
aspirin, warfarin, Lovenox, and the novel anticoagulants for VTE prophylaxis in post-operative 
TKAs. Study outcomes included VTE prevention, bleeding risk, and cost. Reversal agents were 
also examined. Findings of this author’s literature review demonstrated that currently, no one 
superior medication exists for prophylaxis of VTE events in patients undergoing TKA (Cafri et 
al., 2017). However, current research indicates that both factor Xa inhibitors and aspirin have 
emerged as the medications of choice. Of the two, aspirin is commonly favored as it does not 
require laboratory monitoring, it is cost effective, and it is available over the counter.  It also has 
less risk of major bleeding compared to factor Xa inhibitors.  
Keywords: TKA DVT prophylaxis, pharmacology, aspirin, Xa inhibitors, LMWH, 
warfarin, VTE prophylaxis cost TKA, diagnosing DVT  
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INTRODUCTION 
Elective total knee arthroplasty (TKA) is the most frequently performed inpatient surgical 
procedure in the United States, with an estimated 700,000 TKAs performed in 2010 and a 
projected 3.48 million procedures per year by 2030 (Kurtz, Ong, Lau, Mowat, & Halpern, 2007). 
Well-known complications of this procedure include DVT and PE, collectively referred to as 
VTE. Without utilization of prophylactic measures, the reported risk of venographically 
documented DVT in patients undergoing TKA ranges from 41-85%. Since the implementation of 
VTE prophylaxis, a reduction in VTE events of 0.6-1% during hospitalization and 2-3% at three 
months postoperatively has been reported (Kakkar & Rushton-Smith, 2013). Various 
pharmacological agents exist for the purpose of VTE prophylaxis. Such agents include aspirin, 
clopidogrel, warfarin, LMWH, and novel anticoagulants including factor Xa inhibitors and DTIs. 
The American College of Chest Physicians (ACCP) and the American Academy of Orthopedic 
Surgeons (AAOS) initially had differing views regarding the superior VTE prophylaxis regimen 
for patients undergoing major orthopedic surgery, which includes TKA. However, as of 2012, 
the ACCP and AAOS have both approved of the sole use of aspirin as a means of VTE 
prophylaxis (Stewart & Freshour, 2013). The ACCP recommends use of LMWH, fondaparinux, 
dabigatran, apixaban, rivaroxaban, low-dose unfractionated heparin (UFH), vitamin K 
antagonists, or aspirin for a minimum of ten to fourteen days postoperatively (Falck-Ytter et al., 
2012). The AAOS recommends using prophylaxis but does not currently endorse a single, 
superior medication (AAOS, 2011).   
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STATEMENT OF THE PROBLEM 
Many potential pharmacologic options for VTE chemoprophylaxis exist, each with a 
unique profile of benefits, risks or side effects, and cost. These factors, along with patients’ 
medical history, must be considered when determining the most suitable option for VTE 
chemoprophylaxis. To date, no singular “gold standard” therapy is recommended for VTE 
prophylaxis following TKA. 
RESEARCH QUESTIONS 
Among the current pharmacologic options for VTE prophylaxis following TKA, does a 
superior drug or combination of drugs exist based on patient outcomes?  
Which of the current pharmacologic VTE prophylaxis options demonstrates the greatest 
cost effectiveness with the fewest risks?  
METHODOLOGY 
PubMed and Science Direct were utilized to find research articles regarding outcomes of 
different medications for VTE prophylaxis in patients undergoing TKAs. Because of the 
different functionality of the search engines, different MeSH terms were used to obtain the 
appropriate articles. MeSH terms that were utilized to obtain relevant articles in PubMed 
included the following: “Arthroplasty, Replacement, Knee, Venous Thrombosis/prevention and 
control” [Mesh] , “Aspirin”[Pharmacological Action], “Warfarin” [Pharmacological Action], “ 
Factor Xa Inhibitors” [Pharmacological Action], “Lovenox,” [Pharmacological Action], “Cost” 
[Mesh] and “Treatment Outcomes” [Mesh]. In Science Direct, search terms utilized included the 
following: “VTE prophylaxis TKA aspirin,” “Aspirin AND Warfarin And Xa inhibitors AND 
VTE Prophylaxis,” and “TKA AND Xa inhibitors AND enoxaparin.” Lastly, “VTE prophylaxis 
for orthopedic surgery patients” was used to search for current guidelines in Dynamed Plus. 
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Publications examined for this literature review were peer reviewed articles published within the 
past ten years.  
LITERATURE REVIEW 
Review of the literature confirmed the existence of several pharmacologic options for 
VTE prophylaxis in post-operative management of patients undergoing TKA. The pharmacology 
of medications included in this literature review was obtained from various credible textbooks 
and research articles. Studies were included if the patient population underwent a TKA and did 
not have a preexisting condition requiring preoperative anticoagulation therapy. Only studies 
performed within the last 10 years were reviewed. Study participants were all adults.  
DVT Pathophysiology, Risk Factors, and Diagnosis 
The coagulation cascade is initiated by the release of tissue factor, which is stimulated by 
any tissue trauma and/or vascular injury. Once released, tissue factor forms a complex with 
factor VIIa which, in the presence of calcium, cleaves clotting factors IX and X to their activated 
forms, IXa and Xa (Adams, Anger, Greenwood, & Fanikos, 2013). The activation of these 
factors allows the prothrombinase complex to attach to a phospholipid membrane. This 
combination results in the breakdown of prothrombin to thrombin (Adams et al., 2013). 
Thrombin is one of the most potent activators of both primary (platelet mediated) and secondary 
(clotting factor mediated) hemostasis. Thrombin may also potentiate clot formation by fibrin 
polymerization, platelet receptor activation, endothelium activation, and activation of factors V, 
VIII, XI, and XIII (Adams et al., 2013). Anticoagulation agents work by alternating the various 
pathways within the coagulation cascade or by targeting thrombin directly, which ultimately 
interferes with clot formation. On the other hand, indirect inhibitors target and bind to naturally 
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occurring plasma cofactors, increasing their interaction with clotting factors to disrupt the 
cascade (Adams et al., 2013). 
German physician Rudolf Virchow identified three major facets of thrombus formation; 
these include venous stasis, endothelial injury, and hypercoagulation and are known collectively 
as “Virchow’s Triad.”  Patients undergoing TKAs typically meet all three components of the 
triad: venous stasis in the form of postoperative immobilization, endothelial and vascular injury 
as the result of surgical trauma, and postoperative release of tissue factor that renders a transient, 
low-level hypercoagulable state. Increased levels of plasminogen activator inhibitor 1 (PAI-1) 
are also associated with a decrease in fibrinolytic activity on the first postoperative day (Kneeper 
& Thomas, 2014).  
Some researchers have further investigated venous stasis in postoperative TKA patients. 
Sasaki et al., (2009) researched venous hemodynamic alterations in lower extremities following 
total joint arthroplasty, including TKA and total hip arthroplasty (THA). Utilizing Doppler 
ultrasonography, they measured preoperative and postoperative venous flow volumes. They 
found the mean venous flow velocities (MVFV) at three days postoperatively and at one week 
postoperatively were significantly lower than preoperative MVFV. However, at two or more 
weeks postoperatively, no significant difference from preoperative MVFV was noted. Because 
venous stasis has a fundamental role in thrombus formation, the results of this study 
demonstrated that the highest risk of developing a DVT is during the initial two-week 
postoperative period; after two weeks postoperatively, the risk decreases (Sasaki et al., 2009). 
Physicians must carefully consider VTE risk factors prior to clearing patients for total 
joint arthroplasty. Researchers have found that older age (greater than 70 years), female sex, high 
BMI (greater than 30), malignancy, bilateral surgery, cemented fixation, and prolonged surgery 
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time (greater than two hours) place patients at higher risk for developing VTE (Zhang et al., 
2015). Other VTE risk factors include history of VTE, diabetes mellitus, hypertension, varicose 
veins, general anesthesia, and hormone replacement therapy (Bauersachs, 2012). Protective and 
preventive factors include chemoprophylaxis and early mobilization. By identifying high-risk 
patients preoperatively, clinicians can plan for more intensive treatment and closer monitoring to 
better prevent DVT.  
DVTs are difficult to diagnose with physical exam alone, and clinical diagnosis relies 
most heavily on the presence and analysis of risk factors. The most common symptoms 
associated with DVT include leg pain and swelling; however, most DVTs produce no symptoms. 
(Patel, 2017). Special physical examination testing includes Homan’s sign, which signifies DVT 
if the patient exhibits calf pain with passive dorsiflexion of the foot. Objective evidence of DVT 
is found in fewer than 50 percent of patients with the aforementioned signs and symptoms (Patel, 
2017). Clinical workup of a suspected DVT consists of a blood test called a D-dimer and/or a 
venous duplex ultrasound. The D-dimer is only helpful when negative, as a positive D-dimer can 
signify many other pathological and non-pathological events. The venous duplex ultrasound is 
the most practical diagnostic tool because it is noninvasive, easily repeatable, and inexpensive. 
The inability to visualize compressibility of a vein with real-time, B-mode Doppler ultrasound is 
more than 95 percent sensitive and specific for detecting proximal DVT (Kassai et al., 2004). 
However, the gold standard for DVT diagnosis is more invasive contrast venography, which 
demonstrates an intraluminal defect in the presence of a DVT (Kassai et al., 2004).  
The majority of orthopedic patients with PE are also asymptomatic unless the embolism 
is large enough to increase pulmonary resistance, which results in right sided heart failure and 
hypoxemia (Bauersachs, 2012). Symptomatic patients most commonly present with chest pain 
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and sudden-onset shortness of breath. Physical exam findings associated with PE include 
tachypnea and pulmonary crackles (Bauersachs, 2012). The gold standard for PE diagnosis is 
pulmonary angiography; however, less invasive computed tomography (CT) angiography is 
more commonly used for diagnosis. If the embolism is large enough to impede all 
cardiopulmonary function, immediate death can ensue.  
Pharmacology and Pharmacokinetics of Current Chemoprophylaxis Agents 
Several VTE chemoprophylaxis options exist for patients undergoing TKAs. Clinicians 
must be aware of the pharmacology and pharmacokinetics of each agent so as to choose the most 
appropriate agent in light of each patient’s co-morbidities, allergies, and risk factors. Knowledge 
of each agent’s mechanism of actions, adverse side effects, potential drug interactions, and 
reversal agent is required.  
Aspirin non-selectively and irreversibly inhibits cyclooxygenase, reducing prostaglandin 
and thromboxane A2 synthesis, ultimately inhibiting platelet aggregation (Fleisher, Roizen & 
Roizen, 2017). It is metabolized in the stomach and excreted in the urine. Because its metabolism 
occurs in the stomach, aspirin ingestion may irritate the stomach lining and potentiate gastric 
ulcer formation with chronic use. Other common side effects of aspirin include dyspepsia, 
nausea, vomiting, and bleeding (Fleisher et al., 2017). Common dosing for VTE prophylaxis is 
81 milligrams (mg) twice daily for six weeks postoperatively following TKA. A reversal agent 
does exist in the case of overdose or excessive bleeding. To reverse any antiplatelet agent used in 
the last 24 hours, the patient should be given platelets (one pack or six units of donor platelets) 
and desmopressin (DDAVP) (0.3 micrograms(mcg)/kilogram(kg) DDAVP in 50 milliliters (mL) 
normal saline given over 15 to 30 minutes). DDAVP is a synthetic antidiuretic hormone 
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analogue and works by increasing plasma levels of factor VIII and von Willebrand factor, which 
are important in the coagulation cascade (DeLoughery, 2015). 
Factor Xa inhibitors such as rivaroxaban and apixaban work by inhibiting the common 
pathway of the coagulation cascade. Clot formation is dependent upon the activation of factor X 
to factor Xa via the intrinsic and extrinsic pathways (Alquawaizani, Buckley, Adams, & Fanikos, 
2013). Factor Xa inhibitors inhibit clot formation by selectively and reversibly blocking the 
active site of factor Xa. They also inhibit free and clot-bound factor Xa and prothrombinase 
activity (Alquawaizani et al., 2013). Uniquely, factor Xa inhibitors have a short half-life of five 
to twelve hours. Thus, in the case of accidental overdose, normal dosing can resume just one day 
following such an event (Alquawaizani et al., 2013). The dosing regimen for apixaban is 2.5 mg 
12-24 hours after surgery followed by 2.5 mg twice daily for 12 days (“Apixaban,” 2017). 
Currently, no Food and Drug Administration (FDA) approved reversal agent exists for factor Xa 
inhibitors; however, a promising drug is currently undergoing phase III trials (Husted, Verheugt, 
& Comuth, 2015). This drug, andexanet alfa, is designed to neutralize the anticoagulant effects 
of both direct and indirect factor Xa inhibitors. Andexanet is a recombinant modified human 
factor Xa decoy protein that is catalytically inactive but retains the ability to bind factor Xa 
inhibitors at the active site with high affinity and a 1:1 stoichiometric ratio (Husted et al., 2015). 
Andexanet binds and sequesters factor Xa inhibitors within the vascular space, thereby restoring 
the activity of endogenous factor Xa and reducing levels of anticoagulant activity (Husted et al., 
2015).  
Lovenox is a LMWHs that, like the novel factor Xa inhibitors, inhibit factor Xa in the 
common pathway of the coagulation cascade. Additionally, Lovenox works to inhibit thrombin 
by binding to and potentiating the effects of antithrombin III (Alquawaizani et al., 2013). 
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Lovenox prevents the propagation and growth of formed thrombi but does not dissolve existing 
clots. Like aspirin and factor Xa inhibitors, no monitoring is required; however, the medication 
must be injected subcutaneously. Heparin-induced thrombocytopenia (HIT) is a risk of any 
LMWH, though the risk is lower than that associated with unfractionated heparin (Alquawaizani 
et al., 2013). A reversal agent, protamine sulfate, is available. Protamine sulfate is given 
intravenously; upon contact with heparin, the drug forms salts that neutralize heparin’s 
anticoagulant effects (Alquawaizani et al., 2013). If the last dose of Lovenox was fewer than 
eight hours ago, then one mg of protamine per one mg of enoxaparin should be administered. If 
the last dose was between eight and twelve hours ago, then 0.5 mg of protamine per one mg of 
enoxaparin should be administered. If over 12 hours have passed since the last dose, then 
protamine may not be required (Symthe et al., 2016). 
Historically, warfarin was the most popular agent for VTE prophylaxis following TKA. 
Currently other agents are preferred and prescribed, but warfarin remains the agent of choice for 
patients with mechanical heart valves. Warfarin works by inhibiting vitamin K-dependent 
coagulation factors, including factors II, VII, IX, and X, and proteins C and S (Alquawaizani et 
al., 2013). Patients taking warfarin are required to undergo frequent blood draws to assess the 
international normalized ratio (INR), which is used to determine whether the warfarin level is 
therapeutic. For DVT prophylaxis following TKA, the goal INR is two to three. Because 
warfarin inhibits a naturally occurring vitamin, foods containing vitamin K may counteract its 
effects; such foods include kale, spinach, and broccoli. Warfarin is also protein bound, so 
malnourished patients or postoperative patients consuming fewer calories due to nausea may 
demonstrate altered warfarin levels. Dosing is titrated or decreased based on INR results, and 
frequent dosage changes are often required. If the INR becomes supratherapeutic, various 
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reversal agents exist; the most appropriate agent depends on the severity and the urgency to 
reverse anticoagulation. Intravenous vitamin K works within 12-24 hours, fresh frozen plasma 
works within one to four hours, and prothrombin clotting complex (PCC) works immediately 
(Hatfield & Chen 2014). PCC contains factors II, VII, IX, and X and proteins C and S and is 
typically reserved for trauma patients requiring immediate surgical intervention (Alquawaizani et 
al., 2013). 
Efficacy of Aspirin, Direct Factor Xa Inhibitors, Warfarin, and LMWH in VTE 
Prophylaxis in Patients Undergoing TKA 
In a systematic review, Vincent, V. G., Phan, K., Yadin, L., & Warwick, B. (2009) 
examined the efficacy of aspirin in preventing VTE in patients undergoing THA or TKA. The 
researchers performed a systematic review and meta-analysis via electronic searches using Ovid 
Medline, PubMed, Cochrane Central Register of Controlled Trials (CCTR), Cochrane Database 
of Systematic Reviews (CDSR), and the Database of Abstracts of Review of Effectiveness 
(DARE) during June 2015. The researchers only included studies involving arthroplasty patients 
given solely aspirin for VTE chemoprophylaxis. Researchers required that the studies reported 
both VTE and secondary outcomes related to chemoprophylaxis complications, such as major 
bleeding (gastrointestinal bleed, intracranial hemorrhage, and any bleeding requiring surgical 
intervention) and wound oozing during post-surgical follow-up. Of the 39 total studies included 
in the meta-analysis, 11 relevant studies qualified for inclusion. The overall rates of DVT and PE 
in the THA and TKA populations were 1.2% and 0.6%, respectively. The rate of major bleeding 
was 0.3%, and the pooled mortality rate was 0.2%. The researchers concluded that aspirin used 
both alone and in combination for thromboprophylaxis resulted in a low rate of VTE and major 
bleeding complications. This study demonstrated aspirin can be used as a sole means of VTE 
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prophylaxis in postoperative TKA patients. This conclusion is supported by the AAOS and 
ACCP. 
Additionally, Wilson, Poole, Chauhan, & Rogers, (2016) performed a systematic review 
of 13 total studies investigating the efficacy of aspirin for DVT prophylaxis compared to 
warfarin, enoxaparin, factor Xa inhibitors, and direct thrombin inhibitors following THA and 
TKA. Of the 13 total studies, only a few were of acceptable quality (level 1), with most of the 
other studies demonstrating flaws and potential bias in their research methods and results. 
Evidence from one high quality randomized controlled trial (RCT) of 778 patients showed no 
difference in the rates of VTE in patients given aspirin or LMWH following TKA. A total of four 
RCTs investigated VTE prophylaxis in TKA alone. The first studied aspirin and LMWH groups 
in 778 patients. No significant difference was demonstrated between aspirin and LMWH in rates 
of VTE or wound problems, although a trend (p=0.091) toward increased wound complications 
with LMWH was observed. The second RCT had an unclear of bias and identified no significant 
difference in the rates of asymptomatic VTE with aspirin and pneumatic compression versus 
LMWH and pneumatic compression in 274 patients. An increased post-operative drain volume 
was seen with aspirin (p=0.03), but this was not associated with an increased requirement for 
transfusion. The third RCT had an unclear risk of bias and compared aspirin, LMWH, and 
rivaroxaban in 324 patients. The incidence of asymptomatic DVT was significantly higher in the 
aspirin group versus the rivaroxaban group (16.4% versus 2.9%, p=0.014), although no 
significant difference in rates of symptomatic DVT existed. Wound complications and average 
hidden blood loss, which represents all perioperative blood loss and is calculated by the change 
in pre- and postoperative total body red blood cell content, were both higher with rivaroxaban 
compared to aspirin (4.9% versus 1.8%, p=0.014, and 1.7 liters (L) versus 1.3 L, p=0.04). No 
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statistically significant difference existed between aspirin and LMWH in any outcome measure. 
The fourth RCT pertaining specifically to TKA compared aspirin and LMWH followed by 
rivaroxaban in 120 patients. This RCT demonstrated an unclear risk of bias and demonstrated no 
statistical difference in rates of asymptomatic DVT, but blood loss was higher in the LMWH and 
rivaroxaban groups (p≤0.05). One level III study had a serious risk of bias and compared aspirin 
with warfarin in THA and TKA in 696 patients. Overall, an increased rate of VTE was seen in 
the aspirin group. Subgroup analysis revealed this effect was limited to TKA. 
A total of four RCTs compared aspirin with LMWH. One high quality RCT with 778 
participants showed aspirin was non-inferior to LMWH (p≤0.001) for the prevention of VTE in 
TKA, with a trend toward increased wound complications with LMWH (p=0.09). Another 
showed no difference in rates of VTE in TKA in 274 patients but did show increased post-
operative drain volume with aspirin (p=0.03). The third included 121 patients and showed an 
increased rate of DVT in patients taking LMWH compared with aspirin and pneumatic 
compression in TKA and THA (p=0.002). Subgroup analysis showed this effect was confined to 
THA. The final RCT reported no significant difference in rates of DVT or wound complications 
in 324 TKA patients among the aspirin and LMWH groups.  
A total of three studies compared aspirin with dabigatran, all of which carried a moderate 
risk of bias. A paper examining 1728 patients demonstrated a decreased rate of symptomatic 
VTE, wound complications, and length of stay with aspirin compared to dabigatran in TKA and 
THA. All patients received LMWH as inpatients and aspirin or dabigatran as outpatients (Wilson 
et al., 2016). Another study showed decreased time to wound dryness (3.2 versus 6.4 days, 
p≤0.01) with aspirin in 110 patients undergoing THA and TKA (Wilson et al., 2016). A final 
study of 123 patients compared wound discharge and length of stay among postoperative THA 
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patients and demonstrated increased wound discharge and length of stay in the dabigatran group 
compared to the LMWH (for inpatient DVT prevention) and aspirin (for DVT prevention upon 
discharge) group. Rivaroxaban in TKA was evaluated by two RCTs. The first study with 120 
patients showed no difference in asymptomatic DVT rate and no wound complications in either 
group but higher blood loss with rivaroxaban compared to aspirin, LMWH and dabigatran 
groups. The second trial, examining 324 patients, showed fewer asymptomatic DVTs with 
rivaroxaban but no difference in symptomatic DVTs and a significantly increased rate of wound 
complications and hidden blood loss with rivaroxaban. Wilson et al. (2016) concluded that 
insufficient evidence existed to establish one medication as superior and that each had a unique 
side effect profile to be considered on a case-by-case basis. 
Huang, Parvizi, Hozack, Chen & Austin (2016) compared the efficacy of aspirin to that 
of warfarin in patients undergoing a total joint arthroplasty (TJA). The researchers performed a 
retrospective study analyzing 30,270 patients who received aspirin or warfarin for VTE 
prophylaxis after primary or revision TJA between January 2000 and June 2014. The researchers 
compared the efficacy of aspirin versus warfarin in both low-risk and high-risk populations as 
well as the complication rates of both therapies. Patients were considered higher risk if they had 
a history of chronic obstructive pulmonary disease, active hypercoagulable disorder, history of 
VTE, active malignancy, pulmonary hypertension, or stroke. Patients were also considered 
higher risk if they had a combination of lesser risk factors that met a minimum cumulative 
threshold, including older age, anemia, CHF, peripheral vascular disease, and a history of 
myocardial infarction. The incidences of symptomatic VTE, acute periprosthetic joint infection 
(PJI), gastrointestinal complications, and mortality within 90 days of surgery were recorded. The 
results of the study revealed that the 90-day postoperative VTE rate and incidence of 
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postoperative complications were significantly lower in both lower- and higher-risk aspirin 
groups compared to warfarin groups. The incidence of VTE in the lower risk patients receiving 
aspirin was 0.2%; the risk was 0.6% in higher risk patients; this was significantly superior to 
warfarin, which resulted in a 1.8% incidence of VTE in the lower risk group and 3.2% in the 
higher risk group (p<0.001). The incidence of PE was 1.8% in the higher risk warfarin group and 
0.1% in the higher risk aspirin group (p<0.001). The incidence of DVT was 1.7% in the higher 
risk warfarin group and 0.5% in the higher risk aspirin group (p=0.017). The incidence of DVT 
in the lower risk aspirin group was 0.1% in the lower risk group compared to 0.8%. Aspirin also 
demonstrated less risk of postoperative joint infection and gastrointestinal complication. The 
incidence of acute PJI was 1.7% in the higher risk VTE group receiving warfarin compared to 
0.1% in the higher risk VTE group receiving aspirin (p=0.001). The gastrointestinal complication 
rate was 0.6% in the higher risk warfarin group compared to 0.0% in the higher risk aspirin 
group (p=0.054). The 90-day mortality rate was 1.1% in the higher risk warfarin group compared 
to 0.1% in the higher risk aspirin group (p=0.016).  
Stewart and Freshour (2013) compared the 2011 AAOS guidelines for the use of aspirin 
to prevent VTE to recommendations from the ACCP. Also included in this study was a literature 
search to identify clinical trials that evaluated the use of aspirin as monotherapy or in 
combination with another method of prophylaxis (pneumatic compression devices) for 
prevention of VTE in high-risk patients. Researchers utilized only meta-analyses or RCTs from 
1986 or after, published in English. After analysis, researchers were unable to conclude whether 
aspirin was a safe and effective option for VTE prophylaxis in high-risk patients undergoing 
THA, TKA, or hip fracture surgery. They concluded that enough validation existed for 
practitioners to use aspirin as the sole means of VTE prophylaxis, but not enough validation 
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existed to recommend a change to sole use of aspirin for practitioners who currently use a more 
potent anticoagulant.  
Ma, Zhang, Wu, Wang & Ying (2015) performed a systematic literature search of 
multiple databases to identify studies that met their inclusion criteria comparing rivaroxaban or 
apixaban and enoxaparin. The authors performed a meta-analysis of six RCTs including 13,790 
patients published between 2005 and 2010. Three of the six studies compared the outcomes of 
apixaban with enoxaparin regarding DVT, PE, and major bleeding, while the other three studies 
investigated rivaroxaban. Overall, the incidence of DVT was significantly decreased with the use 
of direct Xa inhibitors (twice daily dosing) other than enoxaparin (RR=0.68, 95% CI: 0.59-0.78, 
p<0.01). Subgroup analysis of three apixaban studies yielded similar results (RR=0.68, 95% CI: 
0.59-0.79, p<0.01). However, further analysis stratified by the regimen of enoxaparin did not 
reveal a significant difference between apixaban and 30 mg twice daily enoxaparin (RR=0.85, 
95% CI: 0.66-1.10, p<0.01.) Pooled analysis of three studies that used direct Xa inhibitors with 
once daily dosing demonstrated a significantly lower incidence of DVT compared to enoxaparin 
(RR=0.60, 95% CI: 0.50-0.73, p<0.01), and a similar result was obtained from the pooled 
analysis of two studies of rivaroxaban (RR=0.59, 95% CI: 0.48-0.72, p<0.01). No significant 
difference existed between direct Xa inhibitors (twice daily dosing) with enoxaparin regarding 
PE (RR=1.94, 95% CI: 0.96-3.92, p=0.06). Similar results were obtained with respect to the 
stratification analyses: apixaban and enoxaparin (RR=2.00, 95% CI: 0.97-4.12, p=0.06). The 
pooled analysis demonstrated no significant difference between direct factor Xa inhibitors and 
enoxaparin in terms of major bleeding.  
A systematic review performed by Neuman et al. (2012) evaluated the risks and benefits 
of oral direct factor Xa inhibitors versus LMWH in patients undergoing TKA or THA. The 
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researchers utilized databases to find and analyze 22 RCTs. Of the 22 RCTs, 11 included patients 
undergoing THA, and 10 included patients undergoing TKA. One study included patients 
undergoing either procedure. In all trials, a mandatory venography was done within the last week 
of prophylactic treatment to detect asymptomatic DVT. The results of the study revealed that, 
when compared to LMWH, factor Xa inhibitors were associated with a reduced incidence of 
symptomatic DVT (CI, 0.30-0.70).  In the analysis that directly examined absolute differences, 
researchers found a reduction of three DVT events (CI, 1-5 fewer events) per 1000 treated 
patients over one to five weeks with factor Xa inhibitors. Using the baseline risk from an 
observational study of 26 patients who underwent hip or knee replacement and received 
thromboprophylaxis, researchers calculated that use of direct factor Xa inhibitors would result in 
four fewer DVT events (CI, 3-6 fewer events) per 1000 patients treated. The pooled effect 
estimate for nonfatal PE suggested no important difference between factor Xa inhibitors and 
LMWH (CI, 0.65 to 1.73). The pooled effect estimate for major bleeding and bleeding leading to 
reoperation was not statistically significant but suggested the possibility of a harmful effect. In 
the analysis that directly examined absolute differences, researchers found an increase of two 
major bleeding events (CI, 0-4 more events) per 1000 patients treated for one to five weeks. 
Intracranial bleeding was assessed by twelve studies, and two events were reported (1 
intracranial bleeding event in the control group in each study). Researchers found an association 
between the dose used in the intervention group and the risk of major bleeding. Lower (CI, 0.70-
1.34) and intermediate (CI, 0.84-2.85) doses of factor Xa inhibitors failed to establish or refute 
an increase in bleeding, but high doses increased the risk for major bleeding (CI, 1.38-4.53). The 
same tendency was observed for the outcome of bleeding leading to reoperation, although the 
test for interaction across the three doses was not significant (p=0.56). After adjusting for dose, 
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researchers found no association between drug and effect on thrombosis (p=0.98), effect on 
bleeding (p=0.21), risk for bias, or length of treatment. Researchers also conducted a meta-
analysis on major bleeding. Moderate and high doses of factor Xa inhibitors caused more major 
bleeding events than LMWH and low doses of factor Xa inhibitors. No difference was observed 
between LMWH and low doses of factor Xa inhibitors.  
King, Pow, Dickison, & Vale (2016) performed a retrospective analysis using a single 
surgeon to compare the safety and efficacy of apixaban and enoxaparin in VTE prophylaxis 
following TKA. The study included 506 patients from 2009 to 2015 that received either apixaban 
or enoxaparin following TKA performed by one surgeon. The primary outcome researchers 
assessed was total in-hospital VTE events; secondary outcomes measured included bleeding 
complications, VTE mortality, and all-cause mortality. The authors hypothesized apixaban 
would demonstrate superior safety and efficacy. Specific criteria regarding dosage and timing of 
medication administration were required. Patients underwent Doppler ultrasonography between 
days three and seven postoperatively. All tests were two-sided, and p-values ≤ 0.05 were 
considered statistically significant. In the group of 506 patients, 253 (50%) received apixaban as 
thromboprophylaxis, and 253 (50%) received enoxaparin. Thirteen lower limb Doppler 
ultrasound results were missing and therefore were not included in the DVT analyses. One 
record did not contain hemoglobin results and hence was not included in the analysis of 
postoperative bleeding. Overall, of the thirty-three patients that developed VTE while in the 
hospital, eleven of those were receiving apixaban, and 22 were receiving enoxaparin. Three of 
the patients with a DVT suffered a subsequent PE; two in the enoxaparin group and one in the 
apixaban group. Bleeding and fatality outcomes were also analyzed. Ten patients experienced a 
postoperative drop in hemoglobin ≥20 g/L that either necessitated two or more units of blood, 
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caused hemodynamic instability, or both. This outcome was more common in the enoxaparin 
group, occurring in 9/253 (3.6%) compared to 1/252 (0.4%) in the apixaban group (p=0.020). 
There was no difference in this outcome between anticoagulant groups (4.7% vs 7.1%, p=0.254). 
Thirty-five patients experienced other bleeding events, with twenty-five (9.9%) in the enoxaparin 
group and ten (4.0%) in the apixaban group (p=0.009). There was one fatality in total; this was 
attributed to PE and occurred in the enoxaparin group. 
Fuji et al. (2014) performed a RCT that was a phase three trial that compared the safety 
and efficacy of daily oral edoxaban beginning six to twenty-four hours postoperatively versus 
twice daily subcutaneous enoxaparin beginning twenty-four to thirty-six hours postoperatively 
for 11-14 days. Authors of the study assessed patients undergoing unilateral TKA. Authors 
excluded patients at high risk of complications, such as those with an increased risk of bleeding 
or VTE, severe renal impairment, hepatic dysfunction, pregnant or lactating women, and those 
with a body weight under 40 kg. The patients were randomly assigned to either the edoxaban or 
enoxaparin group. Researchers utilized a double-blind, double-dummy design to improve the 
validity of the study. They used venography of the operative extremity to detect DVT; this was 
performed within 24 hours of administration of the final dose of study medication or within 96 
hours if it could not be obtained within 24 hours. Venography was repeated at 25-35 days 
following administration of the final dose of study drug. Primary outcome measures assessed 
included VTE events and safety endpoints including major bleeding, clinically relevant, non-
major bleeding, all bleeding, and adverse events. Of 716 patients enrolled, 360 and 356 were 
randomized to receive edoxaban or enoxaparin, respectively. The primary efficacy outcome 
occurred in 22/299 (7.4%) in the edoxaban group and 41/295 (13.9%) patients in the enoxaparin 
group (relative risk reduction = 46.8%), indicating non-inferiority (p<0.001) and superiority 
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(p=0.010) of edoxaban versus enoxaparin. In the edoxaban group, major bleeding occurred in 
4/354 (1.1%) compared to 1/349 (0.3%) in the enoxaparin group (p=0.373). Major and clinically 
relevant, non-major bleeding occurred in 22/354 (6.2%) in the edoxaban group compared to 
13/349 (3.7%) in the enoxaparin group (p=0.129).  
Bala, Huddleston, Maloney & Amanatullah (2017) utilized Humana and Medicare 
databases from 2007 to 2015 to gather and analyze TKA cases. The purpose of this study was to 
determine whether differences in VTE incidence existed for patients undergoing primary TKAs 
depending on whether they were administered aspirin, warfarin, enoxaparin, or factor Xa 
inhibitors. The authors also sought to analyze the bleeding risk associated with each of the four 
aforementioned agents. Finally, the authors assessed how the use of these agents has changed 
with time. Researchers included 1,016 patients given aspirin, 6,096 given enoxaparin, 6,096 
given warfarin, and 5,080 given factor Xa inhibitors. To determine whether patients experienced 
a VTE, the authors searched for specific VTE diagnosis codes at two weeks, 30 days, six weeks, 
and 90 days postoperatively. They also utilized the Charlson Comorbidity Indices and Elixhauser 
Comorbidity Profile to establish criteria to determine high-risk patients. Study results revealed a 
difference in the incidence of DVT at 90 days (p<0.01). Factor Xa inhibitors had the lowest 
incidence of DVT (2.9%) followed by aspirin (3.0%), enoxaparin (3.5%), and warfarin (4.8%). A 
difference in the incidence of PE at 90 days was also noted (p<0.01). Factor Xa inhibitors had 
the lowest incidence of PE (0.9%) followed by enoxaparin (1.1%), aspirin (1.2%), and warfarin 
(1.6%). A difference in the incidence of postoperative anemia at 90 days also existed (p<0.01). 
Aspirin had the lowest incidence of postoperative anemia (19%) followed by warfarin (22%), 
enoxaparin (23%), and factor Xa inhibitors (23%). Researchers also found a difference in the 
incidence of blood transfusion at 90 days (p <0.01). Aspirin had the lowest incidence of a blood 
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transfusion (7%) followed by factor Xa inhibitors (9%), warfarin (12%), and enoxaparin (13%). 
No difference in bleeding-related complications existed among the groups (p = 0.81). Aspirin use 
increased at a compound annual growth rate of 30%, enoxaparin at 3%, and factor Xa inhibitors 
at 43%, while warfarin use decreased at a compound annual growth rate of -3%. 
The authors concluded factor Xa inhibitors were associated with the lowest incidence of 
DVT and PE at 90 days. However, at two weeks and at 30 days, aspirin had the lowest DVT 
incidence. At six weeks, both aspirin and factor Xa inhibitors shared the lowest incidence of 
DVT. Warfarin, throughout the 90 days, was associated with the highest DVT incidence. Factor 
Xa inhibitors exhibited the lowest incidence of PE at 90 days. Aspirin was associated with the 
lowest incidence of postoperative anemia and need for blood transfusion but did not demonstrate 
statistically significant superiority regarding bleeding-related complications. Finally, the authors 
concluded that factor Xa inhibitors and aspirin exhibited the highest rates of growth in utilization 
from 2007 to 2015, at 43% and 30%, respectively. 
Cafri et al. (2017) researched the comparative safety and efficacy of aspirin, LMWH, 
factor Xa inhibitors, and vitamin K antagonists for VTE prophylaxis following TKA. 
Researchers utilized data from the Kaiser Permanente Total Joint Replacement program, which 
included patients receiving unilateral TKA from May 2006 to December 31, 2013. Researchers 
reviewed all inpatient and outpatient records within 90 days of the TKA. The presence of a DVT 
required identification by duplex ultrasonography; pulmonary embolism (PE) presence required 
confirmation via CT scan of the chest or ventilation-perfusion (VQ) scan. The authors also 
reviewed safety outcomes including bleeding, infection, wound complication, and mortality. 
Specific dosages and frequencies of medication administration were required. Any deviation 
from the guidelines or addition of medications that could have influenced the outcomes excluded 
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patients from the study. The results of this study revealed that rates of VTEs were comparable 
among prophylaxis groups with the exception of warfarin, which exhibited a slightly higher risk 
of DVT, fondaparinux, which showed a slightly lower risk of PE, and aspirin, which had a 
slightly higher risk of PE. When considering the combined outcome of VTE, aspirin (1.14% 
incidence of VTE) and warfarin (1.12%) were somewhat higher than enoxaparin (1.02%) and 
fondaparinux (0.78%). The researchers concluded that a lack of evidence existed to indicate the 
superiority of any agent relative to aspirin.  
Venker et al. (2017) focused on the safety and efficacy of the novel anticoagulants for the 
prevention of VTE following THA and TKA. Specifically, researchers assessed apixaban, 
fondaparinux, edoxaban, rivaroxaban, and dabigatran. The researchers used a meta-analysis of 
18 double-blind RCTs and calculated the relative risk of each compared to enoxaparin. Of note, 
drug manufacturers sponsored all 18 trials included in the meta-analysis. Results of the apixaban 
studies revealed that 2.5 mg apixaban twice daily compared to 40 mg enoxaparin once daily 
demonstrated a reduction in VTE by 29%. However, no difference existed between apixaban at 
the aforementioned dose versus 30 mg enoxaparin twice daily. Clinically relevant bleeding rates 
were lower with apixaban, but no difference in major bleeding rates was noted. No difference in 
safety or efficacy was noted with dabigatran 150 mg versus 220 mg once daily. Dabigatran 150 
mg daily was associated with a slightly increased risk of VTE compared to enoxaparin. The 
fondaparinux trials revealed that fondaparinux 2.5 mg daily significantly decreased VTE by 
47%; however, an 11-fold increase in relative risk of major bleeding was noted. The four trials 
comparing rivaroxaban to enoxaparin demonstrated rivaroxaban 10 mg daily decreased VTE by 
45%. Rivaroxaban also increased clinically relevant bleeds by 27% but did not significantly 
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increase major bleeds. The two trials comparing edoxaban and enoxaparin showed that edoxaban 
30 mg daily decreased the risk of VTE by nearly 50% and did not increase the risk of bleeding.  
Zou, Tian, Wang, & Sun (2014) compared the safety and efficacy of rivaroxaban, 
LMWH, and aspirin for postoperative TKA VTE prophylaxis. They utilized a prospective RCT 
that included patients undergoing primary unilateral TKA between July 2011 and July 2013. 
Specific requirements regarding surgical technique, postoperative care, and medication dosages 
existed for inclusion in this study. At 12 hours postoperatively, each group received an initial 
dose of either aspirin, LMWH, or rivaroxaban, and all groups were treated with a single daily 
dose of medication for 14 days. All patients were followed for four weeks postoperatively; 
incision sites were assessed, and venous color Doppler ultrasonography was performed at two 
and four weeks. The incidence of DVT was lower in the rivaroxaban group compared to the 
other two groups 3 (2.94%) versus 14 (12.50%) (p<0.029); 3 (2.94%) versus 18 (16.36%) 
(p<0.017). However, hidden blood loss 1.71 (1.19–2.97) versus 1.18 (0.77–2.31), (p<0.009); 
1.71 (1.19–2.97) versus 1.30 (0.61–2.43), (p<0.004) and wound complications, 5 (4.90) versus 3 
(2.67), (p<0.027); 5 (4.90) versus 2 (1.82), (p<0.014) were more common in the rivaroxaban 
group than in the other groups. No significant difference in DVT incidence existed between the 
LMWH and aspirin groups, 14 (12.50%) vs. 18 (16.36%), (p<0.831), hidden blood loss (1.18 
(0.77–2.31) versus 1.30 (0.61–2.43), (p<0.327) or wound complications, 3 (2.67) versus 2 (1.82), 
(p<0.209). No significant difference in the incidence of limb swelling was found among the three 
groups 38 (37.25%) versus 28 (25.00%) versus 24 (21.82%), (p<0.247). The rivaroxaban group 
demonstrated a higher incidence of subcutaneous ecchymosis in the affected extremity than the 
aspirin group 74 (72.55%) versus 54 (49.09%), (p<0.039), but no significant differences existed 
between rivaroxaban and LMWH 74 (72.55%) versus 62 (55.36%), (p<0.193) or between 
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LMWH and aspirin 62 (55.36%) versus 54 (49.09%), (p<0.427). Researchers concluded 
rivaroxaban had a positive anticoagulation effect but demonstrated an increased risk of both 
postoperative blood loss and wound complications. No significant difference in post-TKA DVT 
incidence was found between aspirin and LMWH, and the former can be used as part of a 
multimodal anticoagulation therapy approach. 
Researchers concluded that rivaroxaban had the lowest incidence of DVT followed by 
LMWH, while aspirin had the highest incidence. Of these, only two patients in the aspirin group 
and one patient in the LMWH group had symptomatic DVTs. A higher incidence of occult blood 
loss, wound complications, and subcutaneous ecchymosis existed in the rivaroxaban group 
compared to the other groups. Researchers also concluded no statistically significant difference 
existed between LMWH and aspirin for post-TKA VTE prophylaxis.  
Cost-Effectiveness Among VTE Prophylaxis Agents 
Duran et al. (2012) completed research evaluating the cost-effectiveness of rivaroxaban 
versus enoxaparin for VTE prophylaxis in patients undergoing THA and TKA from a United 
States payer's perspective. Researchers utilized a decision-analytic model that was divided into 
the following three sub-modules according to the patient’s anticoagulation: prophylaxis, post-
prophylaxis, and long-term complications. The researchers considered the following costs: 
medication, medication administration, patient monitoring, diagnosis, and VTE treatment if 
required. They determined that patients undergoing TKA were hospitalized for an average of 
four days postoperatively, while THA patients were hospitalized for three days. This 
determination was made based on a US orthopedic surgery registry database. Medication costs 
were estimated using the medical care component of the Consumer Price Index; estimated costs 
of Medicare reimbursement rates for the diagnosis of VTE were based on a resource use report 
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by McGarry et al. (2004). Duran et al. (2012) also included direct year 2010 medical costs over 
one- and five- year time horizons. Results of the cost-effectiveness analysis were reported in 
terms of symptomatic VTE events avoided. The authors used the RECORD trials I, II, and III 
that compared rivaroxaban versus enoxaparin for VTE prophylaxis in patients undergoing TKA 
or THA. Record I and Record II trials compared rivaroxaban 10 mg daily for average of 35 days 
(31-39) with enoxaparin 40 mg daily for average of 35 days (31-39) (Record I) or 10 to 14 days 
(Record II) respectively in patients undergoing THA. The Record III trial compared 10 mg of 
rivaroxaban once daily for 10-14 days versus enoxaparin once daily for 10-14 days in patients 
undergoing TKA. The researchers found that rivaroxaban was associated with a cost savings of 
$465.74 per patient and prevented an average of 0.0193 symptomatic VTE events per patient. 
Sensitivity analysis demonstrated a cost savings ranging from $293.01 to $848.68.  
Mostafavi, Rasouli, Maltenfort, & Parvizi (2015) examined the cost-effectiveness of 
aspirin compared to warfarin in both THA and TKA. Only TKA results will be discussed. The 
researchers used a Markov cohort cost-effectiveness analysis that compared the costs, health 
benefits, and the costs per quality adjusted life year (QALY) for patients 55 to 85 years of age. 
The Markov model is utilized when a treatment decision involves consideration of continuous 
risk, the timing of events is necessary, and important events may occur more than once a year. 
The results of their analysis revealed aspirin was more cost-effective than warfarin in the 
majority of patients undergoing TKAs. In patients with a high probability of VTE and a low 
probability of bleeding, however, warfarin was more cost-effective.  However, the reduced 
QALY for patients using warfarin was very small compared to those using aspirin, and the extra 
cost of using warfarin was no more than $4000 per patient. By increasing age in the TKA group, 
cost per TKA was $15,117.20 at age 55 to 60 and $24,458.10 by age 85. Two-way sensitivity 
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analysis was performed separately for the 65 to 70 age TKA group. In this analysis, warfarin 
demonstrated the highest VTE risk when risk of major bleeding was assumed to be extremely 
low. 
DISCUSSION 
 Multiple medication options exist for postoperative DVT prophylaxis following TKA.  
Each option possesses a unique mechanism of action and side effect profile; further, variable 
efficacy and associated cost must be considered in analyzing the utility of each option in each 
patient case. Among the agents, aspirin and factor Xa inhibitors have demonstrated the most 
growth in utilization for DVT prophylaxis following TKA; they have demonstrated adequate 
efficacy as well. Factor Xa inhibitors are associated with an increased cost and risk of bleeding, 
but they also exhibit a slightly decreased risk of VTE compared to aspirin. Aspirin demonstrates 
comparable outcomes, with only a slightly increased risk of VTE as noted above and are 
available for a fraction of the cost of factor Xa inhibitors. Warfarin continues to be the drug of 
choice in patients with mechanical heart valves requiring chemoprophylaxis.  
Among the current pharmacologic options for VTE prophylaxis following TKA, does a 
superior drug or combination of drugs exist based on patient outcomes?  
Vincent et al. (2009) performed a systematic review to determine the efficacy of aspirin 
in preventing VTE in patients undergoing a TKA or THA. The researchers concluded that aspirin 
used both alone and in combination for thromboprophylaxis resulted in a low rate of VTE and 
major bleeding complications. This study demonstrated aspirin can be used as a sole means of 
VTE prophylaxis in postoperative TKA patients. This conclusion is supported by the AAOS and 
ACCP; however, limitations of this study must be considered. Aspirin dosages varied among the 
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studies, differences in study design existed, and user-specific differences existed in the 
interpretation of ultrasound to detect DVT.  
In another systematic review performed by Wilson et al. (2016), researchers investigated 
the efficacy of aspirin for DVT prophylaxis compared to other agents following THA and TKA. 
They utilized studies that compared aspirin to warfarin, enoxaparin, factor Xa inhibitors, and 
DTIs. The researchers concluded that insufficient evidence existed to establish one medication as 
superior, and each had a unique side effect profile to be considered on a case-by-case basis. This 
particular article illustrated the importance of individualizing treatments for each patient or 
similar patient groups. The conclusion correlated with statements from the AAOS and ACCP, 
reporting that many options exist for VTE prophylaxis following TKA without a single, 
definitively recommended therapy.  
Stewart et al. (2013) evaluated the suitability of aspirin in prevention of VTE in high-risk 
orthopedic surgery patients. After analysis, researchers were unable to conclude whether aspirin 
was a safe and effective option for VTE prophylaxis in high-risk patients undergoing THA, 
TKA, or hip fracture surgery. They concluded that enough validation existed for practitioners to 
use aspirin as the sole means of VTE prophylaxis, but not enough validation existed to 
recommend a change to sole use of aspirin for practitioners who currently use a more potent 
anticoagulant. This article supported the systematic review and meta-analysis performed by 
Vincent et al. (2016). but also demonstrated the diverse options for VTE chemoprophylaxis 
following orthopedic surgery. Thus, practitioners are afforded a variety of options for VTE 
chemoprophylaxis depending on the patient profile.  
Another study conducted by Huang et al. (2016) compared the efficacy of aspirin to that 
of warfarin in patients undergoing TJA. The researchers compared the efficacy of aspirin versus 
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warfarin in both low-risk and high-risk populations as well as the complication rates of both 
therapies. The results of the study revealed that at 90 days postoperatively, VTE rate and 
incidence of postoperative complications were significantly lower in both lower- and higher-risk 
aspirin groups compared to warfarin groups. This article echoed the results of Vincent et al. 
(2016) and Stewart et al. (2013) articles regarding the benefits of using aspirin as the sole means 
of VTE prophylaxis. This article also revealed the benefits of aspirin compared to warfarin. 
Limitations of this study included differing dosages in aspirin groups (81 mg versus 325 mg), 
lack of randomization, and the sizes of the groups included in the studies. Only 18% of the low-
risk and 11% of the high-risk groups received aspirin, while the remaining subjects received 
warfarin.  
Ma et al. (2015) performed a systematic literature search of multiple databases to identify 
studies that met their inclusion criteria comparing rivaroxaban or apixaban to enoxaparin. The 
results of their study revealed the overall incidence of DVT was significantly decreased with the 
use of factor Xa inhibitors versus enoxaparin.  However, when comparing apixaban and 
enoxaparin at 30 mg twice daily, no statistically significant difference was noted. No significant 
difference existed between factor Xa inhibitors (twice daily regimen) and enoxaparin regarding 
incidence of PE and major bleeding. This study was significant because it compared enoxaparin 
to two different factor Xa inhibitors. Interestingly, enoxaparin also has indirect inhibitory effects 
on factor Xa, inhibiting antithrombin. This study established that the new factor Xa inhibitors, 
acting directly on factor Xa, demonstrate improved VTE prevention.  
Neumann et al. (2012) evaluated the risks and benefits of oral direct factor Xa inhibitors 
versus LMWH in patients undergoing TKA or THA. The results of the study revealed no 
significant difference existed regarding all-cause mortality at the time of anticoagulant therapy 
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cessation. The factor Xa inhibitors did show a significant reduction in symptomatic DVTs 
compared to enoxaparin. The researchers found three to four fewer symptomatic DVT events per 
1,000 treated patients over five weeks in the factor Xa inhibitor group. This study illustrated 
findings similar to those of Ma et al. (2015), demonstrating a distinct advantage of factor Xa 
inhibitors over enoxaparin. The authors concluded that, when comparing low-to-medium dose to 
high-dose factor Xa inhibitors, higher dosages increased the risk of bleeding. Thus, practitioners 
must consider dosage regimens in addition to the risks and benefits of each individual agent 
when prescribing VTE chemoprophylaxis.  
King et al. (2016) revealed outcomes similar to those described by Neumann et al. (2012) 
and Ma et al. (2015). Apixaban, a factor Xa inhibitor, showed VTE prophylaxis results superior 
to those of enoxaparin. The bleeding and mortality outcomes also favored apixaban. The authors 
concluded that apixaban was safer and more effective than enoxaparin. Numerous limitations 
existed in this study. Authors included both unilateral and bilateral TKA patients. The 
enoxaparin group included more bilateral TKA patients, who typically achieve postoperative 
mobilization later than unilateral TKA patients, thus increasing baseline risk of DVT. Further, 
the inclusion criteria were not specific; no screenings were performed for additional risk factors 
such as age, gender, prior VTE, prior cerebral vascular accident, or atrial fibrillation. Another 
potential limitation was that more patients in the apixaban group received tranexamic acid, which 
facilitates coagulation. This could have influenced bleeding-related complications in the 
apixaban group.  
Fuji et al. (2014) performed the STARS E-3 trial comparing the safety and efficacy of 
once daily oral edoxaban beginning six to 24 hours postoperatively versus twice daily 
subcutaneous enoxaparin beginning 24-36 hours postoperatively for 11 to 14 days. The results of 
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this study paralleled the findings of studies performed by King et al. (2016), Ma et al. (2015), 
and Neumann et al. (2012), revealing that a factor Xa inhibitor, specifically edoxaban, was more 
effective than enoxaparin in reducing the incidence of symptomatic PE and symptomatic and 
asymptomatic DVT. Further, edoxaban did not demonstrate an increased incidence of bleeding 
or adverse events compared to enoxaparin. Some limitations of this study existed. Venography 
was performed only on the surgical leg, meaning asymptomatic DVT of the contralateral leg may 
have been missed. Further, the study had a relatively small sample size. 
Bala et al. (2017) performed a study utilizing Humana and Medicare databases from 2007 
to 2015 to gather and analyze TKA cases. The purpose of this study was to determine whether 
differences in VTE incidence existed for patients undergoing primary TKAs depending on 
whether they were administered aspirin, warfarin, enoxaparin, or factor Xa inhibitors. The 
authors concluded factor Xa inhibitors were associated with the lowest incidence of DVT and PE 
at 90 days. However, at two weeks and at 30 days, aspirin had the lowest DVT incidence. At six 
weeks, both aspirin and factor Xa inhibitors shared the lowest incidence of DVT. Warfarin, 
throughout the 90 days, was associated with the highest DVT incidence. Factor Xa inhibitors 
exhibited the lowest incidence of PE at 90 days. Aspirin was associated with the lowest 
incidence of postoperative anemia and need for blood transfusion but did not demonstrate 
statistically significant superiority regarding bleeding-related complications. Finally, the authors 
concluded that factor Xa inhibitors and aspirin exhibited the highest rates of growth in utilization 
from 2007 to 2015, 43% and 30%, respectively. This study demonstrated outcomes similar to 
those previously described, delineating factor Xa inhibitors and aspirin as superior selections for 
VTE prophylaxis.  It also validated the importance of tailoring chemoprophylaxis to each patient 
based on the side effect profiles of the drugs and patients’ past medical history.  
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  Cafri et al. (2017) evaluated the comparative safety and efficacy of aspirin, LMWH, 
factor Xa inhibitors, and vitamin K antagonists for VTE prophylaxis following TKA. 
Researchers utilized data from the Kaiser Permanente Total Joint Replacement program, which 
included patients receiving unilateral TKA from May 2006 to December 31, 2013. The results of 
their study revealed that rates of VTEs were comparable among prophylaxis groups with the 
exception of warfarin, which exhibited a slightly higher risk of DVT, fondaparinux, which 
showed a slightly lower risk of PE, and aspirin, which had a slightly higher risk of PE. The 
researchers concluded that a lack of evidence existed to indicate the superiority of any agent 
relative to aspirin. The conclusion of this study did oppose the outcome of a study by Zou et al. 
(2014), which revealed an advantage of the novel anticoagulants over aspirin. It did, however, 
correlate closely with studies by Vincent et al. (2016), Stewart et al. (2013), and Huang et al. 
(2016). 
Venker et al. (2017) conducted a study focusing on the safety and efficacy of the novel 
anticoagulants for the prevention of VTE following TKA and THA. Specifically, researchers 
assessed apixaban, fondaparinux, edoxaban, rivaroxaban, and dabigatran. Overall, this meta-
analysis showed four of the five novel anticoagulants reduced the rate of VTE compared to 
enoxaparin after TJA. However, the reduced risk of VTE was offset by an increased risk of 
bleeding.  
Zou et al. (2014) compared the safety and efficacy of rivaroxaban, LMWH, and aspirin 
for postoperative TKA VTE prophylaxis. They utilized a prospective RCT that included patients 
undergoing primary unilateral TKA between July 2011 and July 2013. Researchers concluded 
that rivaroxaban had the lowest incidence of DVT followed by LMWH; aspirin had the highest 
incidence. Of these, only two patients in the aspirin group and one patient in the LMWH group 
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had symptomatic DVTs. A higher incidence of occult blood loss, wound complications, and 
subcutaneous ecchymosis existed in the rivaroxaban group compared to the other groups. 
Researchers also concluded no statistically significant difference existed between LMWH and 
aspirin for post-TKA VTE prophylaxis. This study was relevant because it compared aspirin, 
which, based on other studies, is an effective sole therapy for thromboprophylaxis, to one of the 
novel anticoagulants. The results demonstrated one of the novel anticoagulants displayed 
superiority over more traditional options; however, an increased risk of bleeding was also 
associated with the agent.  
In this author’s opinion based on the literature reviewed, no single superior 
chemoprophylactic agent exists to prevent VTE following TKA. Aspirin and factor Xa inhibitors 
such as apixaban have recently become the two most commonly utilized agents for this purpose. 
Each possesses a specific mechanism of action and side effect profile. Neither aspirin nor factor 
Xa inhibitors require monitoring. Currently, no FDA approved reversal agent exists for factor Xa 
inhibitors; however, a reversal agent is currently in phase III trials and shows promising data.  
Which of the current pharmacologic VTE prophylaxis options demonstrates the greatest 
cost effectiveness with the fewest risks?  
 Medication cost incurred by the patient is difficult to determine due to varying insurance 
coverage and out of pocket expenses. A website (www.goodrx.com) was utilized to obtain 
average cost of each medication. The following costs do not include any insurance coverage. The 
cost of 365 aspirin (81 mg tablets) was $5.70. The cost of 60 apixaban (5 mg tablets) was $454. 
The cost of 30 warfarin (5 mg tablets) was $18.25. Finally, the cost of a 30-day supply of 
enoxaparin (40 mg/0.4mL syringes) was $929.65. Clearly aspirin is the most inexpensive option. 
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Duran et al. (2012) evaluated the cost effectiveness of rivaroxaban versus enoxaparin for 
VTE prophylaxis in patients undergoing THA and TKA from a United States payer’s 
perspective. Researchers utilized a decision-analytic model that was divided into the following 
three sub-modules according to the patient’s anticoagulation: prophylaxis, post-prophylaxis, and 
long-term complications. The researchers considered the following costs: medication, medication 
administration, patient monitoring, diagnosis, and VTE treatment if required. They determined 
that patients undergoing TKA were hospitalized for an average of four days postoperatively, 
while THA patients were hospitalized for three days. This determination was made based on a 
US orthopedic surgery registry database. Medication costs were estimated using the medical care 
component of the Consumer Price Index; estimated costs of Medicare reimbursement rates for 
the diagnosis of VTE were based on a resource use report by McGarry et al (2014). The authors 
used the RECORD trials I, II, and III that compared rivaroxaban versus enoxaparin for VTE 
prophylaxis in patients undergoing TKA or THA. 
This particular study conducted by Duran et al. (2012) also revealed that rivaroxaban, a 
factor Xa inhibitor, is more cost effective than enoxaparin. However, many limitations must be 
considered regarding this study. Authors allowed for patients to change from enoxaparin to 
warfarin therapy in the study. Further, many assumptions were made to generalize findings from 
the available data.  
Mostafavi et al. (2015) examined the cost effectiveness of aspirin compared to warfarin 
in TKAs. The researchers used a Markov cohort cost effectiveness analysis that compared the 
costs, health benefits, and the costs per quality adjusted life year (QALY) for patients 55 to 85 
years of age. The results of their analysis revealed aspirin was more cost effective than warfarin 
in the majority of patients undergoing TKAs. In patients with a high probability of VTE and a 
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low probability of bleeding, however, warfarin was more cost effective.  The authors also noted 
that, as patient age increased, the difference in cost between the two drugs decreased. Previously 
evaluated studies exhibited aspirin as an effective VTE prophylactic agent, and this study 
demonstrated it is also a more cost-effective option, another important factor to consider when 
prescribing thromboprophylaxis. 
APPLICABILITY TO CLINICAL PRACTICE 
Multiple medications are both safe and effective in the prevention of VTE events in 
patients undergoing TKA. In the past, warfarin was the most commonly utilized prophylactic 
agent, and it continues to be the agent of choice in patients who have previously undergone heart 
valve repair. However, due to its multiple potential drug interactions, frequent required 
laboratory monitoring of the INR, and difficulty maintaining a therapeutic INR, warfarin is being 
used far less frequently. Clinicians have begun favoring aspirin and factor Xa inhibitors, and 
both of these agents been endorsed by the AAOS and AACP as sole options for management of 
VTE prophylaxis in patients undergoing TKA. 
Several studies, as discussed above, have demonstrated the superiority of aspirin and 
factor Xa inhibitors over LMWH and warfarin in terms of efficacy of DVT prevention. Factor 
Xa inhibitors are costlier and demonstrate an increased bleeding risk compared to aspirin. 
Neither drug requires laboratory monitoring, and once daily and twice daily dosing options are 
available for both drugs.  
After extensive review of the literature, this author’s opinion is that, in low risk patients 
undergoing TKA, aspirin is a safe and effective chemoprophylactic agent for DVT prevention. 
Aspirin has a limited risk profile, is cost effective and available over the counter, and does not 
require laboratory monitoring. The dosing regimen is simple and consists of one 81 mg tablet 
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twice daily for six weeks postoperatively. Further, in the case of overdose, a reversal agent is 
available. Clinicians must be prudent in analyzing each patient’s DVT risk preoperatively so as 
to choose the most superior prophylactic agent based on the patient’s history and anticipated 
period of immobilization.  
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